Vibra of Southeastern Michigan, LLC

Vibra of Southeastern Michigan, LLC was paid $25.68M by Medicaid between Jan 2020 and Dec 2024, across 161 billing codes. Its largest line is G0480, Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed — 26% of everything it billed.

Compared with peers

Next to other Clinical Medical Laboratory providers in Michigan

Rank by total paid#6 of 108

Median peer was paid$588K

This provider vs. median44×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2020	12,225	$958K
2021	83,023	$3.74M
2022	109,717	$4.40M
2023	254,410	$8.18M
2024incomplete	280,154	$8.41M

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
G0480	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed	26%	91,805	50,436	$6.62M
U0003	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r	17%	76,555	67,367	$4.49M
80307	Drug test(s), presumptive, any number of drug classes; immunoassay	9.6%	63,023	34,420	$2.46M
G0483	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed	6.4%	10,073	8,125	$1.63M
87631		6.1%	15,162	14,853	$1.56M
U0005	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2	4.6%	65,788	58,954	$1.19M
87798	Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism	3.4%	6,659	6,455	$886K
G0481	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed	2.3%	5,508	4,480	$585K
87635	Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe	1.8%	12,396	11,539	$464K
82306	Vitamin D; 25 hydroxy, includes fraction(s), if performed	1.6%	20,210	20,100	$420K
87636	Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B	1.2%	2,968	2,935	$311K
87591	Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe	1.2%	11,868	11,643	$297K

149 more codes

87661	Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe	1.2%	11,907	$297K
87491	Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe	1.2%	11,858	$297K
87481		1.1%	3,046	$282K
84443	Thyroid stimulating hormone (TSH)	1.1%	22,457	$274K
80061	Lipid panel	<1%	22,776	$221K
80053	Comprehensive metabolic panel	<1%	27,906	$213K
87502	Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets	<1%	2,862	$200K
82607		<1%	18,529	$190K
87651	Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe	<1%	7,094	$180K
80074		<1%	5,218	$177K
G0482	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed	<1%	1,253	$172K
83013		<1%	3,292	$161K
87801	Infectious agent detection by nucleic acid; amplified probe, multiple organisms	<1%	2,570	$155K
83036	Hemoglobin; glycosylated (A1C)	<1%	21,870	$153K
85025	Blood count; complete (CBC), automated, and automated differential WBC count	<1%	22,174	$125K
82728		<1%	11,859	$117K
87389	Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies	<1%	6,145	$105K
84481		<1%	6,365	$79K
82746		<1%	6,985	$74K
84439		<1%	10,956	$72K
87529		<1%	1,369	$68K
87511		<1%	2,520	$62K
83540		<1%	12,358	$58K
87640		<1%	2,270	$56K
87653		<1%	2,248	$55K
86803		<1%	4,787	$50K
83550		<1%	7,727	$49K
87486		<1%	1,618	$41K
87634		<1%	812	$41K
87086	Culture, bacterial; quantitative colony count, urine	<1%	6,983	$41K
87806		<1%	1,496	$36K
87581		<1%	1,620	$34K
86696		<1%	2,393	$33K
86003		<1%	511	$32K
84153		<1%	2,378	$31K
85027		<1%	6,335	$30K
84403		<1%	1,404	$26K
83735		<1%	4,795	$23K
86038		<1%	2,190	$19K
84702		<1%	1,810	$19K
86695		<1%	1,926	$18K
82670		<1%	884	$18K
87503		<1%	813	$17K
81001		<1%	6,957	$16K
87522	Neg quan hep c or qual rna	<1%	558	$15K
83001		<1%	1,101	$15K
87563		<1%	618	$15K
86592		<1%	4,337	$13K
83002		<1%	907	$12K
87088		<1%	1,950	$12K
87624	Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types	<1%	434	$11K
83880		<1%	384	$11K
84146		<1%	747	$10K
87077		<1%	1,662	$10K
87186		<1%	1,359	$9K
82043		<1%	2,201	$9K
84144		<1%	614	$9K
84436		<1%	2,998	$9K
86769		<1%	287	$9K
87498		<1%	576	$9K
82785		<1%	688	$8K
86140		<1%	2,143	$8K
82784		<1%	515	$8K
87340		<1%	987	$7K
84479		<1%	1,494	$7K
86480		<1%	149	$7K
84550		<1%	1,825	$6K
86431		<1%	1,335	$6K
85651		<1%	1,643	$5K
84100		<1%	1,454	$5K
86376		<1%	406	$4K
86235		<1%	151	$4K
88174		<1%	224	$4K
87480		<1%	280	$4K
82626		<1%	222	$4K
86704		<1%	467	$4K
87660		<1%	277	$4K
83970		<1%	131	$4K
82570		<1%	1,009	$4K
36415	Collection of venous blood by venipuncture	<1%	1,204	$4K
86225		<1%	345	$3K
80048	Basic metabolic panel (calcium, ionized)	<1%	568	$3K
83655		<1%	381	$3K
83690		<1%	671	$3K
84480		<1%	1,443	$3K
88175	Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer	<1%	163	$3K
87510		<1%	223	$3K
86780		<1%	314	$3K
85610		<1%	845	$3K
82150		<1%	555	$3K
86200		<1%	261	$2K
82679		<1%	137	$2K
87625		<1%	74	$2K
85652		<1%	1,101	$2K
82040		<1%	606	$2K
85730		<1%	481	$2K
82627		<1%	122	$2K
83721		<1%	266	$2K
82550		<1%	385	$2K
86706		<1%	232	$2K
84154		<1%	128	$2K
82172		<1%	86	$2K
82248		<1%	401	$1K
86703		<1%	145	$1K
81015		<1%	645	$1K
86901		<1%	591	$1K
84484		<1%	138	$1K
86900		<1%	560	$1K
86708		<1%	126	$1K
86141		<1%	129	$1K
86353		<1%	27	$1K
82533		<1%	83	$922.76
80076		<1%	201	$833.57
84165		<1%	99	$782.39
86709		<1%	134	$750.34
82553		<1%	81	$736.18
87641		<1%	23	$560.90
82274		<1%	41	$496.23
84466		<1%	54	$482.99
84156		<1%	168	$456.36
86705		<1%	82	$439.19
85379		<1%	56	$413.00
86039		<1%	51	$405.31
81003		<1%	259	$390.94
85230		<1%	30	$387.41
81025		<1%	61	$387.29
82947		<1%	158	$383.19
87500		<1%	14	$365.00
84703		<1%	57	$293.27
83516		<1%	30	$245.52
83525		<1%	30	$234.02
86364		<1%	24	$219.31
82977		<1%	44	$217.70
84681		<1%	14	$205.61
85008		<1%	431	$197.54
83695		<1%	16	$158.52
86762		<1%	12	$133.92
85370		<1%	13	$118.82
85660		<1%	27	$102.00
84155		<1%	53	$101.14
82310		<1%	33	$80.84
87081		<1%	16	$74.79
80069		<1%	13	$73.97
85045		<1%	26	$67.31
82247		<1%	17	$66.58
84132		<1%	30	$63.36
85007		<1%	98	$50.23
84520		<1%	28	$47.47
84270		0%	95	$0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialFEGAN, CLINT (SEC/TREASURER)

Same official

Other billing entities under FEGAN, CLINT

Full network →

Provider	Location	Paid
Vibra Physicians LLC	Johnstown, CO	$2.15M

Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.